因素 | SLE合并活动性 结核病组(30例) | SLE合并LTBI 组(16例) | SLE未合并 感染组(60例) | 对照组 (40名) | 统计 检验值 | P值 | 年龄(岁, ±s) | 40.83±12.17 | 39.06±8.78 | 39.72±9.22 | 38.60±10.03 | F=0.299 | 0.826 | 性别[例/名(构成比,%)] | | | | | χ2=0.157 | 0.984 | 男性 | 4(13.3) | 2(12.5) | 9(15.0) | 5(12.5) | | | 女性 | 26(86.7) | 14(87.5) | 51(85.0) | 35(87.5) | | | SLE病程[月,M(Q1,Q3)] | 54.0(7.5,96.0) | 96.0(72.0,180.0) | 96.0(24.0,147.0) | - | Z=6.832 | 0.033 | 糖皮质激素累计使用剂量[g, M(Q1,Q3)] | 9.06(1.80,17.79) | 24.74(6.41,34.98) | 18.19(7.30,34.55) | - | Z=5.138 | 0.077 | 免疫抑制剂疗程[月,M(Q1,Q3)] | 18.0(0.5,46.0) | 27.0(12.0,66.0) | 36.0(0.5,102.0) | - | Z=1.902 | 0.386 | 脏器受累[例(构成比,%)] | 22(73.3) | 12(75.0) | 50(83.3) | - | χ2=1.423 | 0.491 | 肾脏受累[例(构成比,%)] | 10(33.3) | 7(43.8) | 32(53.3) | - | χ2=3.265 | 0.195 | 血液系统受累[例(构成比,%)] | 8(26.7) | 8(50.0) | 21(35.0) | - | χ2=2.501 | 0.286 | 间质性肺炎[例(构成比,%)] | 7(23.3) | 0(0.0) | 5(8.3) | - | χ2=6.888 | 0.032 | 肺动脉高压[例(构成比,%)] | 2(6.7) | 1(6.3) | 3(5.0) | - | χ2=0.116 | 0.944 | 神经系统受累[例(构成比,%)] | 2(6.7) | 2(12.5) | 3(5.0) | - | χ2=1.152 | 0.562 | SLEDAI-2000评分[分,M(Q1,Q3)] | 4.0(2.0,6.0) | 4.0(2.0,6.5) | 4.5(2.0,7.3) | - | Z=2.394 | 0.302 | 重度活动[例(构成比,%)] | 3(10.0) | 0(0.0) | 1(1.7) | - | χ2=4.564 | 0.102 | 中度活动[例(构成比,%)] | 2(6.7) | 2(12.5) | 8(13.3) | - | χ2=0.912 | 0.634 | 轻度活动[例(构成比,%)] | 4(13.3) | 5(31.3) | 21(35.0) | - | χ2=4.708 | 0.095 | 无活动[例(构成比,%)] | 21(70.0) | 9(56.3) | 30(50.0) | - | χ2=3.258 | 0.196 | hsCRP[mg/L,M(Q1,Q3)] | 25.95(4.00,48.61) | 3.29(1.09,5.00) | 1.13(0.49,3.73) | - | Z=23.027 | <0.001 | ESR[mm/1h,M(Q1,Q3)] | 46.00(31.00,72.25) | 18.50(7.75,35.25) | 20.00(7.75,30.25) | - | Z=11.588 | 0.003 | 补体3(g/L, ±s) | 0.82±0.38 | 0.74±0.33 | 0.73±0.29 | - | F=0.879 | 0.418 | 补体4[g/L,M(Q1,Q3)] | 0.16(0.09,0.23) | 0.08(0.05,0.13) | 0.13(0.07,0.22) | - | Z=3.098 | 0.212 | IgG(g/L, ±s) | 16.32±6.17 | 13.36±8.47 | 13.34±5.09 | - | F=2.636 | 0.076 |
|